Abstract By examining 19 human cell lines derived from brain tumors for altered expression of expressed sequence tags (ESTs) in chromosomal band 4q21-22, we detected loss of expression, in 10 cell lines, of two sequences, WI6336 and WI7913. Both corresponded to the c-Jun NH 2 -terminal kinase (JNK) 3. In the present study, genomic cloning revealed that the JNK3 gene consists of 14 exons interrupted by 13 introns; its transcription-initiation site is within exon 3 and the termination codon lies in exon 14. Fluorescence in situ hybridization (FISH) and radiation-hybrid mapping confirmed the gene to 4q21-22. Together with prior evidence that, in JNK3-deficient mice, the JNK3 signaling pathway mediates apoptosis in central nervous tissue, our results suggest that loss of expression of the JNK3 gene may play an important role in the development of brain tumors in humans.
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Shoko Yoshida · Koichi Fukino · Haruhito Harada Hisaki Nagai · Issei Imoto · Johji Inazawa Hiroshi Takahashi · Akira Teramoto · Mitsuru Emi (Simons et al. 1999) , esophageal adenocarcinomas (Rumpel et al. 1999) , and oral squamous cell carcinomas (Wang et al. 1999) ; we ourselves have defined a 1-cM region at chromosome 4q21-22 that is commonly deleted in hepatocellular carcinomas (Bando et al. 1999) .
The JNK3 gene is a member of the c-Jun NH 2 -terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases and is specifically expressed in the brain (Gupta et al. 1996) . In JNK3-deficient mice, the JNK3 signaling pathway has been shown to mediate apoptosis in the central nervous system (Yang et al. 1997) . Other members of the group, the JNK1 and JNK2 genes, were localized to chromosome 10 and chromosome 5q35, respectively. All isoforms from these genes have a conserved Thr-Pro-Tyr motif in protein kinase subdomain VIII, and differ in their interaction with substrates, that is, ATF2, Elk-1, and Jun transcription factors.
Because the downregulated expression of critical genes, in addition to the mutational inactivation of classical tumor suppressors, may be associated with tumorigenesis, we evaluated the expression of genes located in the 4q21-22 region, by carrying out reverse transcription-polymerase chain reaction (RT-PCR) experiments to amplify expressed sequences in tumor-cell lines. In the present study, we show that, among 12 expressed sequence tag (EST) markers in the 4q21-22 region, 2, which corresponded to the JNK3 gene, showed loss of expression in 10 of 19 cell lines derived from brain tumors; we also describe the genomic structure of the JNK3 gene and its chromosomal localization and single-nucleotide polymorphisms.
Materials and methods
Strategy for expression analysis using ESTs within the 4q21-22
Expressed sequence tags (ESTs) from an interval flanked by D4S3011 and D4S2929 on 4q21-22 (human GeneMap 99 and Whitehead Institute Genome Database) were obtained The c-Jun NH 2 -terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors Introduction Allelic losses (loss of heterozygosity; LOH) in specific chromosomal bands that occur frequently in human cancers suggest that tumor suppressor genes are present within the affected regions. For example, human cancers frequently show LOH on the long arm of chromosome 4, e.g., breast carcinomas (Shivapurkar et al. 1999) , osteosarcomas from Genome Systems (St. Louis, MO, USA) and verified by sequencing. Each clone was examined for altered expression in brain-tumor cell lines by a semiquantitative RT-PCR method, using given primer sets.
Cell culture A total of 19 brain-tumor cell lines were analyzed: A172, BT1, BT2, BT3, BT4, BT5, BT6, D283 Med, Daoy, DBTRG-05MG, GI-1, KG-1-C, SW1088, SW1783, TE671-2, U251, U-118MG, U-138MG, and U-373MG. The cells were donated either by the Cell Resource Center for Biomedical Research at the Institute of Development, Aging and Cancer, Tohoku University; or by the Institute of Physical and Chemical Research (Riken) Cell Bank, Tsukuba, Japan (RCB); or purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA). Each cell line was cultured under the optimized conditions recommended by its distributor.
DNA and RNA extraction and reverse transcription (RT) DNA was extracted from 36 brain-tumor samples, obtained at surgery at Nippon Medical School Hospital, by phenolchloroform procedures described previously . Total RNA from 19 brain-tumor cell lines was extracted using a detergent reagent, following procedures described elsewhere (Kitamura et al. 1999) . Each mRNA was prepared from 1 ϫ 10 8 cells by the oligo-dT cellulose method (FastTrack 2.0 Kit; Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Reverse-transcriptions were carried out using a SMART (Switching Mechanism At 5Ј end of RNA Transcript) RACE (rapid amplification of cDNA ends) cDNA amplification kit (Clontech, Palo Alto, CA, USA) following the manufacturer's instructions.
Polymerase chain reaction and RT-PCR Each PCR was performed in a 30-µl reaction volume, containing 10 pmol of each primer, 1ϫ PCR buffer with 1.5 mM MgCl 2 , and 0.5 units of Taq DNA polymerase, for 27 cycles, a condition that we empirically determined to enable comparison of gene-expression levels by means of ethidiumbromide staining after electrophoresis in agarose gels. Thermo-cycle conditions for amplification were described previously Watanabe et al. 1998) . To quantify the expression levels relative to other genes, we carried out duplex PCR experiments using primers to amplify Glucose-3-phosphate dehydrogenase (G3PDH) (forward, 5Ј-ACCACAGTCCATG CCATCAC-3Ј; reverse, 5Ј-TCCACCACCCTGTTGCTG TA-3Ј) as an internal control (Fig. 1) .
Cloning a full-length cDNA To obtain the full-length cDNA sequence of JNK3, the gene corresponding to two ESTs that showed downregulation, we carried out 5Ј rapid amplification of cDNA ends (5Ј RACE) experiments using the partial cDNA sequence of the JNK3 gene deposited in the GenBank database under accession no. HSU34820, and a SMART RACE cDNA amplification kit (Clontech). In brief, poly(A) RNA from a human heart (Clontech), was first reverse-transcribed with Superscript II reverse transcriptase (GIBCO-BRL, Gaithersburg, MD, USA), using an oligo(dT) primer. First-strand cDNA was subjected to two rounds of PCR as follows: the first reaction employed an outer adapter primer (AP1) and a gene-specific primer (5ЈCACTTCCACACTGTAGAACTGGTTGTCAACTTTG-3Ј) that corresponded to nucleotides 217-250 of the archived partial cDNA. An aliquot of the first PCR reaction mixture was used as a template for nested PCR, using the nested adapter primer AP2 and a nested gene-specific primer (5Ј-GGCAATTTTCACATCCAATGTTGGTT CACTGCAG-3Ј), corresponding to nucleotides 115-148 of the partial cDNA. The PCR products were resolved by electrophoresis in a 1% agarose gel; the specific PCR product visualized by ethidium-bromide staining was purified with a gel extraction kit (Qiagen, Tokyo, Japan) and subcloned using an AdvanTAge PCR cloning kit (Clontech). The nucleotide sequence of the cDNA was determined by the BigDye Terminator cycle sequencing method, using a 377 ABI Prism automated DNA sequencer (Perkin-Elmer, Norwalk, CT, USA).
Isolation of the human JNK3 gene
A bacteriophage P1-derived artificial chromosome (PAC) library and a bacterial artificial chromosome (BAC) library containing human genomic DNA pooled in a threedimensional structure (Genome Systems, St. Louis, MO, USA; Research Genetics, Buffalo, NY, USA) were used to isolate genomic clones of JNK3. These libraries were screened by a PCR method described previously ), using two oppositely oriented oligonucleotides (forward, 5Ј-TGACATCTCCTCCATG TCCA-3Ј; reverse, 5Ј-AGTAA GCATCATTGGAAGA AGACC-3Ј) for screening the PAC library (exons 4-14). For screening the BAC library, we used three primer sets, consisting of (forward) 5Ј-ATCTCAGATCTTCACTATGG-3Ј and (reverse) 5Ј-TGTATGGTTTCTCATCTATA-3Ј (exon 3); (forward) 5Ј-GAGCCCAGAGGGATTTTG-3Ј and (reverse) 5Ј-TCAATTTAGAGAGCTGCGTG-3Ј (exon 1); and (forward) 5Ј-GTATTTATGAGCCTCCATTTC-3Ј and (reverse) 5Ј-CTGACAAAAGGCAATTTTCAC-3Ј (exon 2). The BAC primers corresponded respectively, to EST (WI7913), to nucleotides 1-78 of the partial cDNA, and to the sequence we obtained by 5Ј RACE. Escherichia coli cells containing positive clones were cultured in the presence of kanamycin or chloramphenicol, and PAC or BAC DNA inserts were isolated as described previously ).
Sequence analysis of exon/intron junctions
Nucleotide sequences of exons and their boundaries were determined by direct sequencing of the PAC or BAC clones, or by long and accurate (LA)-PCR, using primers designed from the archived partial cDNA sequence of JNK3. Primers for sequencing the exon/intron junctions of exons 1 and 2 were designed from the full-length JNK3 cDNA we obtained by 5Ј RACE. Sequencing was performed by the BigDye Terminator cycle sequencing method, using a 377 ABI Prism automated DNA sequencer (Perkin Elmer). The size of each intron was estimated by PCR amplification, using LA Taq (Takara, Tokyo, Japan) with two oppositely oriented primers located in the exons flanking each intron.
Fluorescence in situ hybridization (FISH)
A PAC clone carrying the human gene was used as a probe for FISH analysis, which was carried out as described by Mukae et al. (1998) . The PAC DNA was labeled with biotin-16-2Ј-deoxy-uridine-5Ј-triphosphate (biotin-16-dUTP) by nick-translation and hybridized to denatured chromosomes, at a final concentration of 25 ng/ml in 50% formamide, 10% dextran sulfate, 2 ϫ standard saline citrate (SSC), 0.2 mg/ml Cot-1 DNA (GIBCO/BRL), 2 mg/ml salmon sperm DNA, and 2 mg/ml E. coli tRNA. The hybridized signals were detected with fluorescein isothiocyanateavidin (Boehringer Mannheim, Mannheim, Germany).
Cells were counterstained with 4Ј,6-diamidino-2-phenylindole, and the slides were examined through a Nikon epifluorescence microscope (Nikon, Tokyo, Japan), equipped with a charge-coupled device (CCD) camera (Photometrics, Tucson, AZ, USA). Images were captured with Quips (Vysis, Tokyo, Japan) software and processed with Adobe Photoshop 3.0 software (Adobe systems, San Jose, CA, USA).
Radiation-hybrid mapping
The G3 RH mapping panel from the Stanford Human Genome Center (Boehnke et al. 1991) , was used to confirm and define further the chromosomal location of the JNK3 gene. Typing was carried out using opposing primers located in the introns flanking exon 1 (forward: 5Ј-TCTGTTGAGTCTGCACACTG-3Ј; reverse: 5Ј-AGGA ATACATTAGGAATGCCG-3Ј), exon 2 (forward: 5Ј-TCAAACTCATCTGTTTTTTGGC-3Ј; reverse: 5Ј-AGATCCTAGTTTTCATGCTAAG-3Ј), exon 3 (forward: 5Ј-GTATAGTACAGGTCAAGATAAGG-3Ј; reverse: 5Ј-GGAATGTATGCAAATGGTATGTC-3Ј), and exon 5 (forward: 5Ј-TGAGTTGCTCTTGGATCTC-3Ј; reverse: 5Ј-ATCTTACAAACTCCACTGC-3Ј). The results of maximum-likelihood analysis were obtained by submitting the raw scores to http://www-shgc.stanford.edu.
Single-strand conformational polymorphism (SSCP) analysis with silver staining
To look for possible alterations in the JNK3 gene, we amplified each exon and its flanking regions with appropriate primers (Table 1) , in genomic DNAs from 36 primary brain tumors. About 10 ng of each PCR product was heatdenatured in the presence of deionized 80% formamide and electrophoresed in 8% polyacrylamide gels, with or without 10% glycerol, in 0.5 ϫ tris-borate/EDTA (TBE), at 8 V/cm for 10 h at room temperature (Hirayama et al. 1998) . DNA fragments were visualized by silver staining, using the Plus One DNA silver-staining kit (Pharmacia Biotech, Tokyo, Japan). Each fragment showing an altered SSCP band pat- GGAATGTATGCAAATGGTATGTC  266  4  CTTGCCTCATGTTTTTGCTG  TTCCCTTTAAAAATACAGCAAATCC  242  5  TGAGTTGCTCTTGGATCTC  ATCTTACAAACTCCACTGC  201  6  TCTTTCTCTCGTTTCCTCTG  CCCTTCCTTCATGAGTTTTG  127  7  ACTAACACTGTGGATTCACC  AATTGTAATCCTAGAGAAGGTG  195  8  TTAATTTTTTCCCTTATCCTTACTG  TTTGATGCTGCTCTCCGAA  223  9  CTCCTTCAGAAGTCAATTATC  TGCTTCTATCTTTACTCTCCTGG  242  10-a  TTGAAAGGCTAGTGGTCTGC  CCGATTCTCCACATAGTTTC  154  10-b  GAAGAAATTGCAACCCACAG  CCCTCATAGTTGTCCTCAAG  164  11  GAAATCAAAATCTTACTAATTGTTTTTCTC  AAGCAAAGTAAAGGCAGCCT  198  12  GTATTCTCGTGCATTGTAAGAG  GCCTTGTTGATACTTTCTGAG  204  13  AATTTCCCTGTGGATGAAGG  CTAGTTTATTGGTTATTCACGG  171  14  ATGGGTCTGGTTCTAGATTG  ATTGACAGACGAGGATGGAG  101 PCR-SSCP, Polymerase chain reaction-single-strand conformation polymorphism tern was subcloned with an AdvanTAge PCR cloning kit (Clontech) and sequenced.
Results and discussion
Among ESTs from an interval flanked by D4S3011 and D4S2929 at 4q21-22, two (WI6336 and WI7913) showed loss of expression in 10 of the 19 brain-tumor cell lines examined. These two ESTs were found to be parts of the JNK3 gene, as they corresponded to the archived partial cDNA sequence (Genbank no. HSU34820). Because JNK3 is selectively expressed in the brain, and a study of JNK3-deficient mice had indicated that the JNK3 signaling pathway mediates apoptosis in the nervous system, we considered that loss of expression of this gene might be associated with tumorigenesis in the human brain. To search for alterations in the JNK3 gene, we characterized it at the genomic level and carried out PCR-SSCP experiments in brain tumors.
Genomic structure of the JNK3 gene
We invoked the 5Ј RACE technique to identify an additional 200-bp sequence on the 5Ј end of the partial JNK3 cDNA, and subjected the result to a basic local alignment search tool (BLAST) search; 132 bp of this sequence exactly matched the human MAP kinase mRNA archived as HSU07620 in the GenBank database. The genomic region containing the human JNK3 gene was cloned in a PAC (98k4) and three BACs (269j1, 81k15, 171m15). The entire gene was found to consist of 14 exons interrupted by 13 introns (Fig. 2) . The boundary sequences are shown in Table 2 . Exon 6 was the smallest, at 59 bp; other exons ranged in size from 64 to 434 bp. Sequences at the exon-intron boundaries for all 13 introns were compatible with the consensus sequence for splicing junctions, including GT-AG (Mount 1982) .
Comparison of genomic and cDNA sequences revealed that exons 1 and 2, and the 5Ј half of exon 3, encode the 5Ј untranslated region (UTR), while the 3Ј portion of exon 3 clones that cover the region are shown above the map. Conserved protein-kinase subdomains (Hanks et al. 1988 ) are indicated by Roman numerals The lowercase letters refer to intron sequences, and the uppercase letters to exon sequences. The intron sizes were estimated as described in "Materials and methods". Bold face letters indicate consensus sequence for GT-AG rule ND, Not determined through the 5Ј portion of exon 14 encodes the translated region; the remainder of exon 14 encodes the 3ЈUTR (Fig.  2) . The locations of conserved protein-kinase subdomains I-XI (Hanks et al. 1988 ) are also indicated in Fig. 2 . Figure  3 shows the nucleotide sequence of the putative 5Ј-flanking region of the JNK3 gene; no CAAT or TATA box was present in the 5Ј-flanking region of the JNK3 gene. These features are characteristic of the promoters of housekeeping genes (Dynan 1986 ).
Chromosomal localization
When a PAC genomic clone was used as a probe to confirm the localization of the JNK3 gene by FISH, clear signals were present on chromosomal band 4q21-22 (Fig. 4) . The gene was also mapped to chromosome 4q21-22 by means of the G3 RH mapping panel of 83 hybrid cell lines from the Stanford Human Genome Center (Boehnke et al. 1991) , through linkage to marker SHGC4-508, with a logarithm of the odds (LOD) score of more than 12.33.
Sequence variations in the JNK3 gene
We amplified the entire coding region in each of 36 primary brain-tumor samples and screened the PCR products by SSCP analysis, followed by visualization with silver staining. PCR products with potential variations were sequenced directly by automated instruments. By comparing normal samples, we observed two polymorphisms within the JNK3 gene, the first within exon 10 and the other in intron 5. These polymorphisms and their allelic frequencies are summarized in Table 3 . As both variants were observed in normal samples, neither represented a somatic mutation that would account for the loss of expression we observed in tumor cells.
JNK3 gene in brain tumorigenesis
JNK is a member of the MAP group of protein kinases, and it is found in at least ten isoforms that result from the Gupta et al. 1996) . JNK3 is selectively expressed in the brain and, to a lesser extent, in the heart and testis (Gupta et al. 1996) . In JNK3-deficient mice, the JNK3 signaling pathway mediates apoptosis in the nervous system (Yang et al. 1997 ).
The study reported here revealed loss of expression of the JNK3 gene in 10 of the 19 human brain-tumor cell lines we examined. Fresh primary cultures of brain tumors were not tested in the present study, because of unavailability. Future examination of gene expression, using such specimens, will be necessary to confirm role of the JNK3 gene in brain tumorigenesis. Genes that frequently show decreased expression in tumors are characterized as class II tumor suppressors (Zou et al. 1994) . Our results suggest that the JNK3 gene may belong to class II, because (1) it is located at 4q21-22, where LOH is common in tumors; (2) its expression has been lost in multiple lines of brain-tumor cells, and (3) it has not undergone detectable mutations in braintumor samples. Although no class I tumor suppressor has yet been identified from the 4q21-22 region, it is attractive to speculate that the regional inactivation of multiple genes from this chromosomal band contributes to tumor formation (Zou et al. 1994 ). However, because our analysis showed that JNK3 is not a mutational target in brain-tumor cells, it is apparently inactivated by other mechanisms (e.g., allelic loss, methylation, or even haplo-insufficiency). Future studies should include functional analysis of this gene through transfection to cancer cells, or methylation analysis, once the promoter region is identified, to help clarify these issues.
